focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 18th Nov 2013 08:10

AGA Rangemaster: N+1 Singer raises its target price from 150p to 175p and keeps a buy recommendation.APR Energy: Jefferies cuts target price from 1300p to 1260p retaining a buy recommendation.Atkins (WS): LIberum Capital increases target price from 1300p to 1400p maintaining a buy recommendation.Aveva: Panmure Gordon ups target price from 2374p to 2386p and keeps a hold recommendation.Bank of Georgia: Panmure Gordon raises target price from 2200p to 3000p and retains a buy recommendation.Big Yellow Group: Numis raises target price from 460p to 535p keeping an add rating.Cairn Energy: UBS moves target price from 310p to 305p and stays with its buy recommendation.Cape: JP Morgan lowers target price from 299p to 288p and maintains a neutral rating.Carr's Milling: Investec increases target price from 1710p to 1900p and maintains a buy recommendation.Diploma: Jefferies takes target price from 720p to 750p and reiterates a buy recommendation. Numis downgrades from add to hold with a target price of 697p.Drax Group: Liberum Capital raises target price from 640p to 735p upgrading to buy.Euromoney: Investec ups target price from 1200p to 1250p and reiterates a buy recommendation.Foxtons: Canaccord Genuity upgrades to buy woth a target price of 320p.Gem Diamonds: JP Morgan moves target price from 180p to 185p retaining an overweight rating.International Consolidated Airlines Group: Nomura takes target price from 335p to 380p and keeps a buy recommendation.ITE Group: Investec places its target price (prev.: 335p) under review, while keeping its buy recommendation.Lancashire Holdings: Numis raises target price from 865p to 935p and upgrades from hold to add.Lonmin: Investec ups target price from 266p to 287p, but still recommends selling.Majestic Wine: Investec raises target price from 495p to 620p and retains a buy recommendation. Panmure Gordon increases target price from 500p to 635p and stays with its buy recommendation.MITIE Group: Investec ups target price from 310p to 330p and keeps a buy recommendation.New World Resources: Jefferies shifts target price from 70p to 75p and maintains its hold recommendation.Northern Petroleum: Westhouse Securities shifts target price from 123p to 120p, while upgrading to buy.Ocean Wilson Holdings: Cantor Fitzgerald ups target price from 1345p to 1400p and stays with its buy recommendation.Ophir Energy: Canaccord Genuity ups target price from 375p to 400p and retains a hold recommendation.Partnership Assurance: Deutsche Bank reduces target price from 470p to 385p keeping a hold recommendation.SAB Miller: JP Morgan increases target price from 3270p to 3465p and leaves its overweight rating unchanged.Shire: Jefferies raises target price from 3100p to 3400p and keeps a buy recommendation.Summit Corporation: N+1 Singer moves target price from 11p to 16.3p and reiterates a buy recommendation.Ultra Electronics: UBS cuts target price from 1900p to 1820p maintaining a neutral rating. JP Morgan reduces target price from 2100p to 1920p leaving its neutral rating unaltered.Vedanta Resources: Deutsche Bank cuts target price from 1050p to 1020p retaining a hold recommendation. Credit Suisse reduces target price from 1350p to 1270p and leaves its outperform rating unaltered.Volex Group: FinnCap upgrades to hold with a target price of 90p.
More News
24 Feb 2016 12:35

Summit Therapeutics hails strong C-difficile findings

(ShareCast News) - Summit Therapeutics has reported that pre-clinical research into its treatment for the Clostridium difficile hospital superbug has found it to be a "novel and potent antibiotic". A peer-reviewed paper has been produced based on a study of Summit's ridinilazole versus current stand

Read more
19 Jan 2016 12:48

Summit Therapeutics gains worldwide patent protection for C-diff drug

(ShareCast News) - Summit Therapeutics has won a key patent protecting its novel antibiotic, ridinilazole, for the treatment of infections caused by the Clostridium difficile hospital superbug. The patent will grant Summit exclusivity in Europe for the use of ridinilazole in the treatment of CDI unt

Read more
19 Jan 2016 12:18

Summit Therapeutics Gets European Patent For Antibiotic Ridinilazole

Read more
22 Dec 2015 12:02

Port Erin Biopharma Continues To Look For Investments, Swings To Loss

Read more
17 Dec 2015 12:28

Summit Therapeutics Third Quarter Loss Widens As Pipeline Progresses

Read more
17 Nov 2015 12:17

Summit Therapeutics Extends Alliance With University Of Oxford

Read more
18 Sep 2015 12:50

Summit Therapeutics To Present Positive SMT19969 Data In San Diego

Read more
10 Sep 2015 11:11

Summit Therapeutics Finishes Enrolment For Phase II SMT19969 Trial

Read more
27 Aug 2015 11:48

Summit Therapeutics First Half Loss Widens As It Develops Pipeline

Read more
17 Aug 2015 12:33

Summit Therapeutics surges on positive clinical trial update

(ShareCast News) - Shares in Summit Therapeutics surged after the company said that its phase 1B clinical trial of SMT C1100 for the treatment of Duchenne muscular dystrophy met its primary objective and will now move on to a Phase 2 trial. The drug discovery and development company said half of the

Read more
14 Jul 2015 07:25

LONDON BRIEFING: Iran Nuclear Agreement Hits Oil Prices

Read more
13 Jul 2015 11:23

Summit Therapeutics Says Preclincal Data Support Its DMD Treatment

Read more
8 Jul 2015 12:04

Summit Therapeutics receives FDA fast-track decision for new antibiotic

Drug discovery and development company Summit Therapeutics has received approval from the US and Food Drug Administration (FDA) for its novel antibiotic. The FDA granted fast-track designation for the SMT19969 antibiotic which treats both duchenne muscular dystrophy and C. difficile infection (CDI).

Read more
8 Jul 2015 11:22

Summit Therapeutics Says CDI Antibiotic Given Fast Track Designation

Read more
7 Jul 2015 11:24

Summit Therapeutics Gets European Patent For Muscle Disease Treatment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.